| 17th Feb 2020 5:30 pm |
RNS |
Summit Therapeutics |
| 11th Feb 2020 10:00 am |
GNW |
AIM Delisting Reminder |
| 10th Feb 2020 2:15 pm |
GNW |
Director/PDMR Shareholding |
| 6th Feb 2020 12:00 pm |
GNW |
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma |
| 4th Feb 2020 12:00 pm |
GNW |
Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference |
| 27th Jan 2020 7:00 am |
GNW |
Exercise of Restricted Stock Units |
| 24th Jan 2020 12:00 pm |
GNW |
Summit Announces Management Update |
| 23rd Jan 2020 12:00 pm |
GNW |
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work |
| 20th Jan 2020 2:15 pm |
GNW |
Holding(s) in Company |
| 20th Jan 2020 2:15 pm |
GNW |
Holding(s) in Company |
| 15th Jan 2020 12:15 pm |
GNW |
Notification of Transactions of Persons Discharging Managerial Responsibilities |
| 7th Jan 2020 12:00 pm |
GNW |
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection |
| 31st Dec 2019 9:00 am |
GNW |
Holding(s) in Company |
| 30th Dec 2019 7:00 am |
GNW |
Holding(s) in Company |
| 24th Dec 2019 8:30 am |
GNW |
Completion of $50 million Fundraising and Directorate Change |
| 24th Dec 2019 7:01 am |
GNW |
Award of Share Options |
| 24th Dec 2019 7:00 am |
GNW |
Exercise of Restricted Stock Units |
| 23rd Dec 2019 12:00 pm |
GNW |
Result of General Meeting |
| 19th Dec 2019 7:00 am |
GNW |
Timetable Update |
| 17th Dec 2019 12:00 pm |
GNW |
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 |
| 16th Dec 2019 2:15 pm |
GNW |
Notice of Q3 Results |
| 6th Dec 2019 12:00 pm |
GNW |
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting |
| 6th Nov 2019 12:00 pm |
GNW |
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress |
| 4th Nov 2019 12:00 pm |
GNW |
Summit Therapeutics Recognises C. difficile Awareness Month |
| 16th Oct 2019 12:00 pm |
GNW |
Summit Therapeutics to Present at the 2019 BIO Investor Forum |
| 11th Oct 2019 12:01 pm |
GNW |
Directorate change |
| 11th Oct 2019 12:00 pm |
GNW |
Half-year report |
| 10th Oct 2019 2:30 pm |
GNW |
Notice of Results |
| 7th Oct 2019 12:00 pm |
GNW |
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection |
| 3rd Oct 2019 12:00 pm |
GNW |
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care |
| 3rd Oct 2019 7:00 am |
GNW |
Block Listing Six Month Review |
| 1st Oct 2019 2:05 pm |
RNS |
Second Price Monitoring Extn |
| 1st Oct 2019 2:00 pm |
RNS |
Price Monitoring Extension |
| 25th Sep 2019 12:00 pm |
GNW |
Summit Therapeutics to Host R&D Day 7 October 2019 |
| 24th Sep 2019 12:00 pm |
GNW |
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 |
| 18th Sep 2019 7:00 am |
GNW |
Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes |
| 5th Sep 2019 12:00 pm |
GNW |
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference |
| 4th Sep 2019 12:00 pm |
GNW |
Summit Therapeutics to Participate in Upcoming Investor Conferences |
| 1st Aug 2019 12:00 pm |
GNW |
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference |
| 17th Jul 2019 12:00 pm |
GNW |
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress |
